CGC
Canopy Growth Corp
NASDAQ · Pharmaceuticals
$1.10
+0.02 (+1.85%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 1.29B | 1.60B | 165.63M | 156.52M | 143.27M |
| Net Income | -2,876,660,469 | -3,204,994,332 | 21.61M | 22.40M | 20.41M |
| EPS | — | — | — | — | — |
| Profit Margin | -222.4% | -211.2% | 13.1% | 14.3% | 14.3% |
| Rev Growth | -19.2% | -19.2% | +8.2% | +1.7% | +0.2% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 113.90M | 113.90M | 102.64M | 105.38M | 93.00M |
| Total Equity | 170.61M | 170.61M | 378.95M | 454.44M | 415.12M |
| D/E Ratio | 0.67 | 0.67 | 0.27 | 0.23 | 0.22 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | -520,955,343 | -612,661,024 | 29.60M | 28.04M | 26.75M |
| Free Cash Flow | — | — | 16.40M | 15.05M | 13.14M |